Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 14.05 per share at the end of the most recent trading day (a -1.13% change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 1.50B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 76 people. Catalyst Pharmaceuticals Inc. CEO is Patrick J. McEnany.

The one-year performance of Catalyst Pharmaceuticals Inc. stock is -12.66%, while year-to-date (YTD) performance is -24.46%. CPRX stock has a five-year performance of 453.15%. Its 52-week range is between 11.09 and 22.11, which gives CPRX stock a 52-week price range ratio of 26.86%

Catalyst Pharmaceuticals Inc. currently has a PE ratio of 32.10, a price-to-book (PB) ratio of 7.55, a price-to-sale (PS) ratio of 12.90, a price to cashflow ratio of 22.70, a PEG ratio of -, a ROA of 25.63%, a ROC of 28.06% and a ROE of 30.53%. The company’s profit margin is 37.54%, its EBITDA margin is 44.00%, and its revenue ttm is $153.45 Million , which makes it $1.47 revenue per share.

Of the last four earnings reports from Catalyst Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.24 for the next earnings report. Catalyst Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Catalyst Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $19.9, which is +41.64% compared to the current price. The earnings rating for Catalyst Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catalyst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catalyst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.28, ATR14 : 0.52, CCI20 : 104.68, Chaikin Money Flow : 0.08, MACD : 0.36, Money Flow Index : 77.66, ROC : 14.04, RSI : 60.88, STOCH (14,3) : 81.65, STOCH RSI : 0.42, UO : 52.98, Williams %R : -18.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catalyst Pharmaceuticals Inc. in the last 12-months were: Alicia Grande (Option Excercise at a value of $135 500), Alicia Grande (Sold 110 000 shares of value $1 822 313 ), Brian Elsbernd (Option Excercise at a value of $56 500), Brian Elsbernd (Sold 50 000 shares of value $803 450 ), Carmen Jeffrey Del (Sold 0 shares of value $-127 063 ), Carmen Jeffrey Del (Sold 40 000 shares of value $667 810 ), Charles B. O'Keeffe (Option Excercise at a value of $79 000), David S. Tierney (Option Excercise at a value of $39 500), David S. Tierney (Sold 30 000 shares of value $504 900 ), Denkhaus Donald (Sold 0 shares of value $-107 300 ), Donald A. Denkhaus (Option Excercise at a value of $39 500), Elsbernd Brian (Sold 0 shares of value $-56 500 ), Elsbernd Brian (Sold 50 000 shares of value $803 500 ), Gary Ingenito (Option Excercise at a value of $0), Gary Ingenito (Sold 5 918 shares of value $99 718 ), Grande Alicia (Option Excercise at a value of $135 500), Grande Alicia (Sold 110 000 shares of value $1 822 313 ), Harper Molly (Option Excercise at a value of $0), Ingenito Gary (Option Excercise at a value of $0), Molly Harper (Option Excercise at a value of $0), Patrick J. McEnany (Option Excercise at a value of $158 000), Patrick J. Mcenany (Sold 26 151 shares of value $345 978 ), Philip H. Coelho (Option Excercise at a value of $0), Preethi Sundaram (Option Excercise at a value of $0), Richard J. Daly (Option Excercise at a value of $0), Steve Miller (Sold 0 shares of value $-79 000 ), Steven R. Miller (Option Excercise at a value of $0), Sundaram Preethi (Option Excercise at a value of $0)